Geode Capital Management LLC Acquires 682,273 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Geode Capital Management LLC raised its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 23.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,562,758 shares of the company’s stock after buying an additional 682,273 shares during the quarter. Geode Capital Management LLC owned about 1.74% of Taysha Gene Therapies worth $7,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of TSHA. Creative Planning bought a new stake in Taysha Gene Therapies in the 3rd quarter valued at $28,000. Principal Financial Group Inc. purchased a new position in shares of Taysha Gene Therapies during the second quarter valued at about $48,000. China Universal Asset Management Co. Ltd. grew its position in shares of Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Taysha Gene Therapies in the third quarter worth about $85,000. Finally, Scientech Research LLC purchased a new stake in shares of Taysha Gene Therapies in the second quarter worth about $97,000. Institutional investors own 77.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TSHA. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Canaccord Genuity Group increased their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Trading Up 6.9 %

TSHA stock opened at $1.85 on Friday. Taysha Gene Therapies, Inc. has a twelve month low of $1.19 and a twelve month high of $4.32. The stock has a market capitalization of $379.14 million, a price-to-earnings ratio of 2.94 and a beta of 0.79. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm’s fifty day simple moving average is $2.10 and its two-hundred day simple moving average is $2.18.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.